These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 37862796)

  • 1. The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy.
    Tan X; Wang Y; Wu Z; Zhou Q; Tang Y; Liu Z; Yuan G; Luo S; Zou Y; Guo S; Han N; Yao K
    Eur J Cancer; 2023 Nov; 194():113360. PubMed ID: 37862796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic risk stratification derived from individual patient level data for men with advanced penile squamous cell carcinoma receiving first-line systemic therapy.
    Pond GR; Di Lorenzo G; Necchi A; Eigl BJ; Kolinsky MP; Chacko RT; Dorff TB; Harshman LC; Milowsky MI; Lee RJ; Galsky MD; Federico P; Bolger G; DeShazo M; Mehta A; Goyal J; Sonpavde G
    Urol Oncol; 2014 May; 32(4):501-8. PubMed ID: 24332646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative plasma IGFBP2 is associated with nodal metastasis in patients with penile squamous cell carcinoma.
    Hu X; Chen M; Liu W; Li Y; Fu J
    Urol Oncol; 2019 Jul; 37(7):452-461. PubMed ID: 31053522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus infection affects treatment outcomes and the immune microenvironment in patients with advanced penile squamous cell carcinoma receiving programmed cell death protein 1 inhibitor-based combination therapy.
    Wei L; Li Z; Guo S; Ma H; Shi Y; An X; Huang K; Xiong L; Xue T; Zhang Z; Yao K; Luo J; Han H
    Cancer; 2024 May; 130(9):1650-1662. PubMed ID: 38157276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
    Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
    BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations.
    Ali SM; Pal SK; Wang K; Palma NA; Sanford E; Bailey M; He J; Elvin JA; Chmielecki J; Squillace R; Dow E; Morosini D; Buell J; Yelensky R; Lipson D; Frampton GM; Howley P; Ross JS; Stephens PJ; Miller VA
    Oncologist; 2016 Jan; 21(1):33-9. PubMed ID: 26670666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of ID1 promotes tumor progression in penile squamous cell carcinoma.
    Hu X; Chen M; Li Y; Wang Y; Wen S; Jun F
    Oncol Rep; 2019 Feb; 41(2):1091-1100. PubMed ID: 30535485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Advanced Penile Cancer.
    Chahoud J; Kohli M; Spiess PE
    Mayo Clin Proc; 2021 Mar; 96(3):720-732. PubMed ID: 33308870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-138-5p-mediated HOXD11 promotes cell invasion and metastasis by activating the FN1/MMP2/MMP9 pathway and predicts poor prognosis in penile squamous cell carcinoma.
    Tan X; Liu Z; Wang Y; Wu Z; Zou Y; Luo S; Tang Y; Chen D; Yuan G; Yao K
    Cell Death Dis; 2022 Sep; 13(9):816. PubMed ID: 36151071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune landscape and immunotherapy for penile cancer.
    Tang Y; Hu X; Wu K; Li X
    Front Immunol; 2022; 13():1055235. PubMed ID: 36524123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trophoblast cell surface antigen-2: a promising new biomarker and potential therapeutic target in penile squamous cell carcinoma.
    Weiten R; Storz E; Kessler C; Sperber L; Spohn HE; Pfister D; Nestler T; Tolkach Y; Linden F; Wirtz R; von Brandenstein M; Krausewitz P; Heidenreich A
    BJU Int; 2024 Oct; 134(4):615-621. PubMed ID: 38897814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas.
    Stankiewicz E; Prowse DM; Ng M; Cuzick J; Mesher D; Hiscock F; Lu YJ; Watkin N; Corbishley C; Lam W; Berney DM
    PLoS One; 2011 Mar; 6(3):e17517. PubMed ID: 21407808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-exome Sequencing in Penile Squamous Cell Carcinoma Uncovers Novel Prognostic Categorization and Drug Targets Similar to Head and Neck Squamous Cell Carcinoma.
    Chahoud J; Gleber-Netto FO; McCormick BZ; Rao P; Lu X; Guo M; Morgan MB; Chu RA; Martinez-Ferrer M; Eterovic AK; Pickering CR; Pettaway CA
    Clin Cancer Res; 2021 May; 27(9):2560-2570. PubMed ID: 33441293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular stratification by BCL2A1 and AIM2 provides additional prognostic value in penile squamous cell carcinoma.
    Tan X; Chen D; Guo S; Wang Y; Zou Y; Wu Z; Zhou F; Qin Z; Liu Z; Cao Y; Lin C; Yuan G; Yao K
    Theranostics; 2021; 11(3):1364-1376. PubMed ID: 33391539
    [No Abstract]   [Full Text] [Related]  

  • 15. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
    Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
    Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin.
    Fahey CC; Nebhan CA; York S; Davis NB; Hurley PJ; Gordetsky JB; Schaffer KR
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-line programmed death receptor-1 (PD-1) inhibitor and epidermal growth factor receptor (EGFR) blockade, combined with platinum-based chemotherapy, for stage IV penile cancer.
    Yan R; Ma H; Jiang L; Guo S; Shi Y; Sheng X; Zhang Y; Spiess PE; Liu T; Xue T; Chen X; Li Z; An X; Yao K; Zhou F; Han H
    BJU Int; 2023 Feb; 131(2):198-207. PubMed ID: 35704436
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Penile Squamous Cell Carcinoma Patients Undergoing Inguinal Lymph Node Dissection.
    Azizi M; Peyton CC; Boulware DC; Chipollini J; Juwono T; Pow-Sang JM; Spiess PE
    Eur Urol Focus; 2019 Nov; 5(6):1085-1090. PubMed ID: 29937330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective combinatorial immunotherapy for penile squamous cell carcinoma.
    Huang T; Cheng X; Chahoud J; Sarhan A; Tamboli P; Rao P; Guo M; Manyam G; Zhang L; Xiang Y; Han L; Shang X; Deng P; Luo Y; Lu X; Feng S; Ferrer MM; Alan Wang Y; DePinho RA; Pettaway CA; Lu X
    Nat Commun; 2020 May; 11(1):2124. PubMed ID: 32358507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.